Drugs, QTc interval prolongation and final ICH E14 guideline: An important milestone with challenges ahead

Drug Safety

Volumn 28, Issue 11, 2005, Pages 1009-1028

  Shah, Rashmi R ^a  

^a Rashmi Shah Consultancy Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; CETIRIZINE; CISAPRIDE; FENTANYL; GONADORELIN ANTAGONIST; KETOCONAZOLE; MEXILETINE; MOXIFLOXACIN; NEUROLEPTIC AGENT; OCTREOTIDE; OXYTOCIN; PLACEBO; POTASSIUM CHANNEL HERG; QUINIDINE; SILDENAFIL; SOTALOL; SOTAZIDE; TADALAFIL; TERFENADINE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VARDENAFIL; VASOPRESSIN;

CARDIOVASCULAR RISK; ELECTROCARDIOGRAPHY MONITORING; ELECTROLYTE DISTURBANCE; ERECTILE DYSFUNCTION; ETHNIC DIFFERENCE; GENETIC PREDISPOSITION; HEART PROARRHYTHMIA; HEART RATE; HEART REPOLARIZATION; HUMAN; HYPERTENSION; HYPOKALEMIA; HYSTERESIS; MEDICAL DECISION MAKING; PAIN; POTASSIUM CURRENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QT PROLONGATION; REVIEW; RISK ASSESSMENT;

CLINICAL TRIALS; DRUG DESIGN; DRUG EVALUATION; DRUGS, INVESTIGATIONAL; ELECTROCARDIOGRAPHY; GUIDELINES; HUMANS; INTERNATIONAL COOPERATION; LONG QT SYNDROME; RISK ASSESSMENT;

EID: 26944438354     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200528110-00003     Document Type: Review

References (51)

1. Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol 2002; 54: 188-202
2. Priori SG. Exploring the hidden danger of noncardiac drugs. J Cardiovasc Electrophysiol 1998; 9: 1114-6
3. Shah RR. Drugs, QT interval prolongation and ICH E14: the need to get it right. Drug Saf 2005; 28: 115-25
4. Committee for Proprietary Medicinal Products. 'Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products' (CPMP/986/96) [online]. European Medicines Evaluation Agency; 1997 Dec 17; London, UK. Available from URL: http://www.emea.eu.int/ pdfs/human/swp/09896en.pdf [Accessed 2005 Aug 8]
5. International Conference on Harmonisation. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals [online]. Available from URL: http://www.ich.org/ MediaServer.jser?@_ID=2192&@_MODE=GLB [Accessed 2005 Sep 14]
6. International Conference on Harmonisation. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs [online]. Available from URL: http://www.ich.org/MediaServer.jser?@_ID= 1476&@_MODE=GLB [Accessed 2005 Sep 14]
7. Grisanti S, Morganroth J, Shah RR. A practical approach to cardiac safety. Appl Clin Trial. In press
8. Food and Drug Administration. Safety warnings regarding use of fentanyl transdermal (skin) patches [online]. Public Health Advisory, 2005, July 15. Available from URL: http://www.fda.gov/cder/drug/advisory/fentanyl.htm [Accessed 2005 Aug 8]
9. Mauro VF, Bingle JF, Ginn SM, et al. Torsade de pointes in a patient receiving intravenous vasopressin. Crit Care Med 1988; 16: 200-1
10. Charbit B, Funck-Brentano C, Samain E, et al. QT interval prolongation after oxytocin bolus during surgical induced abortion. Clin Pharmacol Ther 2004; 76: 359-64
11. Marfella R, Nappo F, De Angelis L, et al. The effect of acute hyperglycaemia on QTc duration in healthy man. Diabetologia 2000; 43: 571-5
12. Liou SC, Chen C, Wong SY, et al. Ventricular tachycardia after oxytocin injection in patients with prolonged Q-T interval syndrome: report of two cases. Acta Anaesthesiol Sin 1998; 36: 49-52
13. Beasley CM, Mitchell MI, Dmitrienko AA, et al. The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. J Am Coll Cardiol 2005; 46: 678-87
14. Food and Drug Administration. FDA Cardiovascular and Renal Advisory Committee (29 May 2003). Levitra briefing document [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3956B1_05_Bayer-Levitra.pdf [Accessed 2005 Aug 8]
15. Bass AS, Tomaselli G, Bullingham R, et al. Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices. J Pharmacol Toxicol Methods 2005; 52: 12-21
16. McKibbin JK, Pocock WA, Barlow JB, et al. Sotalol, hypokalaemia, syncope, and torsade de pointes. Br Heart J 1984; 2: 157-62
17. Cavero I, Crumb W. The use of electrocardiograms in clinical trials: a public discussion of the proposed ICH E14 regulatory guidance. Expert Opin Drug Saf 2005; 4: 795-9
18. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58: 32-45
19. Shryock JC, Song Y, Wu L, et al. A mechanistic approach to assess the proarrhythmic risk of QT-prolonging drugs in preclinical pharmacologic studies. J Electrocardiol 2004; 37 Suppl.: 34-9
20. Joshi A, Dimino T, Vohra Y, et al. Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models. J Electrocardiol 2004; 37 Suppl.: 7-14
21. Ficker E, Kuryshev YA, Dennis AT, et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 2004; 66: 33-44
22. Kuryshev YA, Ficker E, Wang L, et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 2005; 312: 316-23
23. Wible BA, Hawryluk P, Ficker E, et al. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods 2005; 52: 136-45
24. Kannankeril PJ, Roden DM, Norris KJ, et al. Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart Rhythm 2005; 2: 134-40
25. Pfizer Inc. Briefing document for Zeldox capsules. Psychopharmacological Advisory Committee [online]. Rockville (MD): Food and Drug Administration, 2000 Jul 19. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/ 3619b1a.pdf [Accessed 2005 Sep 2]
26. Rodriguez I, Kilborn MJ, Liu XK, et al. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001; 285: 1322-6
27. Benton RE, Sale M, Flockhart D, et al. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 2000; 67: 413-8
28. Abi-Gerges N, Philp K, Pollard C, et al. Sex differences in ventricular repolarization: from cardiac electrophysiology to torsades de pointes. Fundam Clin Pharmacol 2004; 18: 139-51
29. James AF, Cho SC, Hancox JC. Recent advances in understanding sex differences in cardiac repolarization. Prog Biophys Mol Biol 2005 Jun 24, [Epub ahead of print]
30. Nakagawa M, Ooie T, Ou B, et al. Gender differences in autonomic modulation of ventricular repolarization in humans. J Cardiovasc Electrophysiol 2005; 16: 278-84
31. Mansi IA, Nash IS. Ethnic differences in electrocardiographic intervals and axes. J Electrocardiol 2001; 34: 303-7
32. Ackerman MJ, Tester DJ, Jones GS, et al. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc 2003; 78: 1479-87
33. Ackerman MJ, Splawski I, Makielski JC, et al. Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing. Heart Rhythm 2004; 1: 600-7
34. Sarapa N, Morganroth J, Couderc JP, et al. Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods. Ann Noninvasive Electrocardiol 2004; 9: 48-57
35. Savelieva I, Yi G, Guo X, et al. Agreement and reproducibility of automatic versus manual measurement of QT interval and QT dispersion. Am J Cardiol 1998; 81: 471-7
36. Azie NE, Adam G, Darpo B, et al. Comparing methods of measurement for detecting drug-induced changes in the QT interval: implications for thoroughly conducted ECG studies. Ann Noninvasive Electrocardiol 2004; 9: 166-74
37. Malik M. The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes. PACE 2002; 25: 209-16
38. Malik M, Farbom P, Batchvarov V, et al. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 2002; 87: 220-8
39. Batchvarov VN, Ghuran A, Smetana P, et al. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol 2002; 282: H2356-63
40. Fossa AA, Wisialowski T, Magnano A, et al. Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. J Pharmacol Exp Ther 2005; 312: 1-11
41. Patterson SD, on behalf of Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team. Investigating drug-induced QT and QTc prolongation in the clinic: a review of statistical design and analysis considerations. Drug Inf J 2005; 39: 243-66
42. Webster R, Leishman D, Walker D. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Devel 2002; 5: 116-26
43. Cavero I, Crumb W. Native and cloned ion channels from human heart: laboratory models for evaluating the cardiac safety of new drugs. Eur Heart J 2001; 3 Suppl. K: K53-63
44. Wolpert C, Schimpf R, Veltmann C, et al. Clinical characteristics and treatment of short QT syndrome. Expert Rev Cardiovasc Ther 2005; 3: 611-7
45. Antzelevitch C. Cardiac repolarization: the long and short of it. Europace 2005; 7 Suppl. 2: 3-9
46. Morganroth J. Comparative efficacy and safety of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmias. Am J Cardiol 1987; 60: 1276-81
47. Kang J, Chen X-L, Wang H, et al. Discovery of a small molecule activator of the human ether-ago-go-related gene (hERG) cardiac K+ channel. Mol Pharmacol 2005; 67: 827-36
48. Zhou J, Augelli-Szafran CE, Bradley JA, et al. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol Pharmacol 2005; 68: 876-84
49. Kinter LB, Siegl PKS, Bass AS. New preclinical guidelines on drug effects on ventricular repolarization: safety pharmacology comes of age. J Pharmacol Toxicol Methods 2005; 52: 153-8
50. Lawrence CL, Pollard BE, Hammond TG, et al. Nonclinical proarrhythmia models: predicting torsades de pointes. J Pharmacol Toxicol Methods 2005; 52: 46-59
51. US FDA. Report on 'Stagnation and innovation: challenge and opportunity on the critical path to new medical products'. Rockville (MD): Food and Drug Administration, 2004 Mar. Available from URL: http://www.fda.gov/oc/initiatives/ criticalpath/whitepaper.pdf [Accessed 2005 Jul 23]